Duopharma Biotech Bhd (XKLS:7148) Beneish M-Score: -2.54 (As of Jun. 26, 2026)


XKLS:7148 Duopharma Biotech Bhd XKLS:7148
82 GF Score
Price RM1.20
GF Value RM1.52
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd Beneish M-Score?

Duopharma Biotech Bhd XKLS:7148 82 Beneish M-Score is -2.54 as of Jun. 26, 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 82/100 and a GF Value™ of RM1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 53.68% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.54 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Duopharma Biotech Bhd's Beneish M-Score or its related term are showing as below:

XKLS:7148' s Beneish M-Score Range Over the Past 10 Years
Min: -2.84   Med: -2.41   Max: -1.55
Current: -2.54

During the past 13 years, the highest Beneish M-Score of Duopharma Biotech Bhd was -1.55. The lowest was -2.84. And the median was -2.41.


Duopharma Biotech Bhd Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Beneish M-Score Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.59 -2.54 -2.52 -2.28 -2.47

Duopharma Biotech Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.24 -2.59 -2.52 -2.47 -2.54

XKLS:7148 vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Beneish M-Score falls into.


XKLS:7148
82GF Score
Duopharma Biotech Bhd XKLS:7148
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Duopharma Biotech Bhd for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0244+0.528 * 0.9061+0.404 * 0.8877+0.892 * 1.0378+0.115 * 0.9782
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0485+4.679 * -0.004508-0.327 * 0.9648
=-2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was RM253.1 Mil.
Revenue was 247.88 + 224.686 + 222.486 + 221.782 = RM916.8 Mil.
Gross Profit was 97.305 + 96.052 + 90.743 + 83.053 = RM367.2 Mil.
Total Current Assets was RM824.8 Mil.
Total Assets was RM1,446.5 Mil.
Property, Plant and Equipment(Net PPE) was RM549.7 Mil.
Depreciation, Depletion and Amortization(DDA) was RM45.3 Mil.
Selling, General, & Admin. Expense(SGA) was RM225.2 Mil.
Total Current Liabilities was RM314.5 Mil.
Long-Term Debt & Capital Lease Obligation was RM341.1 Mil.
Net Income was 30.713 + 19.048 + 22.571 + 20.204 = RM92.5 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = RM0.0 Mil.
Cash Flow from Operations was 23.532 + 28.74 + 29.874 + 16.911 = RM99.1 Mil.
Total Receivables was RM238.1 Mil.
Revenue was 262.738 + 193.671 + 208.732 + 218.324 = RM883.5 Mil.
Gross Profit was 93.289 + 75.539 + 76.79 + 74.939 = RM320.6 Mil.
Total Current Assets was RM760.1 Mil.
Total Assets was RM1,402.0 Mil.
Property, Plant and Equipment(Net PPE) was RM563.4 Mil.
Depreciation, Depletion and Amortization(DDA) was RM45.3 Mil.
Selling, General, & Admin. Expense(SGA) was RM207.0 Mil.
Total Current Liabilities was RM198.3 Mil.
Long-Term Debt & Capital Lease Obligation was RM460.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(253.097 / 916.834) / (238.073 / 883.465)
=0.276055 / 0.269476
=1.0244

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(320.557 / 883.465) / (367.153 / 916.834)
=0.362841 / 0.400457
=0.9061

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (824.799 + 549.684) / 1446.457) / (1 - (760.076 + 563.357) / 1402.025)
=0.049759 / 0.056056
=0.8877

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=916.834 / 883.465
=1.0378

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(45.312 / (45.312 + 563.357)) / (45.279 / (45.279 + 549.684))
=0.074444 / 0.076104
=0.9782

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(225.233 / 916.834) / (207.003 / 883.465)
=0.245664 / 0.234308
=1.0485

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((341.086 + 314.502) / 1446.457) / ((460.32 + 198.33) / 1402.025)
=0.453237 / 0.469785
=0.9648

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(92.536 - 0 - 99.057) / 1446.457
=-0.004508

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Duopharma Biotech Bhd has a M-score of -2.54 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.54 mean?
Duopharma Biotech Bhd (XKLS:7148) has a Beneish M-Score of -2.54 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Duopharma Biotech Bhd and its competitors. According to the industry distribution chart, Duopharma Biotech Bhd ranks #422 out of 911 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Duopharma Biotech Bhd's Beneish M-Score too high?
Duopharma Biotech Bhd's current Beneish M-Score is -2.54. Based on the distribution chart, Duopharma Biotech Bhd ranks #422 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #422 out of 911 companies for Beneish M-Score. This puts Duopharma Biotech Bhd in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Beneish M-Score is -2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current Beneish M-Score is -2.54. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Beneish M-Score is -2.54 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • Beneish M-Score: -2.54
  • GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score

Get the complete analysis for XKLS:7148

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.20
Price
RM1.52
GF Value